What is the market's earnings forecast for Evolus next quarter?

What is the revenue and EPS growth rate for Evolus year over year?

What were the key takeaways from Evolus’s earnings call?

What is Evolus's latest dividend and current dividend yield?

What does Evolus do and what are its main business segments?

What is Evolus's gross profit margin?

Did Evolus beat or miss consensus estimates last quarter?

What were the key takeaways from Evolus's earnings call?

- **Revenue Surge**: 21% YoY growth in Q2, driven by neurotoxin and filler sales, with U.S. market recovery and international expansion.
- **Market Leadership**: Gained significant share in injectable aesthetics, with Evolus Portfolio Bundle customers purchasing 2.5x more product.
- **New Product Momentum**: Launched Estyme in Europe and secured Profhilo licensing, targeting $100M+ peak revenue in skin quality category.
- **Profitability Expansion**: Third consecutive quarter of positive EBITDA, with updated 2026 revenue guidance to $333.5M and 13%-15% long-term margin target.
- **Strategic Expansion**: Expanded into Canada, Australia, and New Zealand, and invested in R&D pipeline with Sculpt, Evolysse Lips, and biostimulators.

**【CEO Summary Section】**
- **Revenue Growth**: 21% year-over-year in Q2, driven by neurotoxin and hyaluronic acid gel sales. U.S. neurotoxin market grew at a mid-single-digit rate, while hyaluronic acid gel market returned to positive growth after two years of decline.
- **Market Share Gains**: Evolus gained significant share across the U.S. injectable aesthetics market, with Jeuveau and Evolysse outpacing the market. Global toxin revenue exceeded $75 million, up 21% YoY.
- **New Product Launches**: Launched Estyme in Europe and expanded partnership with Symatese to include Canada, Australia, and New Zealand. Announced licensing agreement with Ipsen for Profhilo, a skin quality product targeting $100+ million peak revenue.
- **Portfolio Strategy**: Introduced the Evolus Portfolio Growth Bundle, with 70% of participating customers purchasing Evolus products, compared to 25% penetration across all customers.
- **Guidance Update**: Raised full-year 2026 revenue guidance to $330-$337 million (midpoint $333.5M), up from prior range. Adjusted gross margin guidance raised to 67.0%-67.5%.

**【CFO Financial Commentary】**
- **Q2 Financials**: Revenue $84.1 million (21% YoY), adjusted EBITDA $4.7 million (third consecutive quarter of profitability). Adjusted gross margin 69%, benefiting from a tariff refund.
- **Expense Management**: Non-GAAP operating expenses $53.3 million (10% sequential increase), driven by customer education and international expansion. Balance sheet cash $45.2 million, with $100 million available under Pharmakon facility.
- **Long-Term Outlook**: Target $450-$500 million revenue by 2028 with 13%-15% adjusted EBITDA margin, supported by scalable commercial infrastructure.

**【Q&A Highlights】**
- **Profhilo Development**: Profhilo will undergo a full PMA process, targeting U.S. launch around 2030. Clinicians view it as complementary to neurotoxins and fillers, with potential to attract new patient segments.
- **Market Trends**: HA market recovery driven by GLP-1 patients seeking aesthetic treatments. Evolysse benefits from co-branded media campaigns emphasizing weight loss benefits.
- **Execution Bandwidth**: Commercial team successfully managing multiple product launches (Estyme, Profhilo) while maintaining profitability. R&D pipeline includes Sculpt (Q4 2026 approval), Evolysse Lips (2028 launch), and biostimulators/hair care exploration.
- **Tariffs**: Jeuveau remains tariff-exempt; Evolysse subject to 10% tariffs. Prudent inventory management to mitigate potential impacts.


EOLS

EOLS

Evolus (EOLS) Financials Overview

EOLS Q2 2026 Earnings

Earnings

EPS

Revenue

Revenue & Expenses

Key Indicators

Income Statement

Trend

Breakdown

Balance Sheet

Trend

Breakdown

Cash Flow

Trend

Breakdown

Revenue Breakdown

By Business

By Region

Dividend

Payout Ratio

Dividend Yield

You can ask Aime